Methodology: 3.5/5
Usefulness: 3.5/5

COVID STEROID 2 Trial Group, Munch MW, et al. JAMA. 2021 Nov 9;326(18):1807-1817. doi: 10.1001/jama.2021.18295.

Question and Methods: This blinded randomized clinical trial compared the effects of 12 mg daily relative to 6 mg daily of dexamethasone in patients with COVID-19 and severe hypoxemia. 
Findings: A daily regimen of 12mg of dexamethasone did not show a statistically significant difference in the number of days alive without life support at 28 days or the secondary outcomes studied.
Limitations:  Limitations include the potential lack of power to detect statistically significant differences for the outcomes as well as changes in the standard of care management of COVID-19 during the trial.  

Interpretation:  This randomized controlled trial did not identify a statistically significant difference. Following the results of this trial, a pre-planned Bayesian analysis demonstrated a high probability of benefit with the intervention. Further studies are needed to better identify the effects of high dose corticosteroids in COVID-19.

By: Dr. Kevin Durr

Journal Club Supervisor: Dr. Jeff Perry



  • Kevin Durr

    Dr. Kevin Durr is an FRCPC Emergency Medicine resident the University of Ottawa

    View all posts
  • Jeff Perry

    Dr. Perry is an Emergency Physician and full Professor in the department of Epidemiology and Community Medicine. He has a special research interest in subarachnoid hemorrhage, TIA and stroke.

    View all posts
  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, associate professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts